Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

Moderna and CytomX to partner in deal worth up to 1.2bn

The companies plan to develop mRNA-based therapies for a wide range of diseases

- PMLiVE

AstraZeneca to acquire CinCor Pharma in deal worth up to $1.8bn

The deal will strengthen AZ’s cardiorenal pipeline through the addition of baxdrostat

- PMLiVE

AbbVie and Immunome agree on multi-year oncology collaboration

The companies will identify up to ten antibody-target pairs using Immunome's discovery engine

- PMLiVE

Pfizer and Gero collaborate on fibrotic disease research

The companies will use data to identify genes and pathways linked to fibrotic diseases

- PMLiVE

Boehringer Ingelheim and 3T Biosciences in cancer research agreement

The immunotherapy company could receive $268m in milestone payments

- PMLiVE

SCIRIS ANNOUNCES APPOINTMENT OF NEW CEO

Porterhouse extends a very warm welcome to Isaac Batley

Porterhouse Medical Group

Virtual Tools for Promoting Diversity in Pharma and Clinical Trials

It is no secret that Pharma (still) has a major diversity problem.

Impetus Digital

- PMLiVE

IGNIFI ANNOUNCES NEW LEADERSHIP TEAM FOR NEXT PHASE OF GROWTH

Creative healthcare marketing agency IGNIFI has announced its new senior leadership team, which includes the appointment of a new Managing Director for 2023 to lead the business into its next...

IGNIFI

- PMLiVE

Research Partnership appoints new CEO

Research Partnership has appointed Gareth Phillips to take over as CEO

Inizio

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

- PMLiVE

GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates

The vaccines produced promising preliminary results in phase 1 trials

- PMLiVE

BioNTech and UK government partner to accelerate mRNA cancer immunotherapies

The partnership hopes to provide personalised therapies for up to 10,000 patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links